Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00302016
Show 272 Study Locations
|Study Director:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|